Neuromeka: Q1 Operating Loss Continues, but Debt Ratio Sharply Improves to 101% Following CB Conversion

Q1 2026 consolidated revenue: KRW 3.0B (vs KRW 3.2B in Q1 2025); operating loss: KRW 4.3B; net loss: KRW 25.7B (including KRW 22.6B loss from CB conversion)
Debt ratio improved drastically from 558% to 101% due to CB conversion; total equity increased from KRW 13.9B to KRW 41.1B
On April 24, 2026, announced a rights offering of KRW 150B and a stock split (0.5 shares per 1 share)
R&D spending at 55.9% of revenue; accumulated deficit of KRW 90.3B
Credit rating maintained at BB-; still within special listing grace period